apl. Prof. Dr. Stefan Krause

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial (2015) Rollig C, Serve H, Huettmann A, Noppeney R, Mueller-Tidow C, Krug U, Baldus CD, et al. Journal article Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial (2015) Roellig C, Bornhaeuser M, Kramer M, Thiede C, Ho AD, Kraemer A, Schaefer-Eckart K, et al. Journal article Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial (2015) Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, et al. Journal article Workshop - Ökonomische Steuerungsmechanismen: Beispiel Hämatologie und Onkologie (2015) Strech D, Deh U, Schmitz S, Guerkan I, Ostermann H, Krause S Journal article, Report Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib (2014) Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, et al. Journal article CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs (2014) Jitschin R, Braun M, Büttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, et al. Journal article Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV (2014) Kalmanti L, Saussele S, Lauseker M, Proetel U, Mueller MC, Hanfstein B, Schreiber A, et al. Journal article Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology (2014) Tacke D, Buchheidt D, Karthaus M, Krause S, Maschmeyer G, Neumann S, Ostermann H, et al. Journal article Older patients with chronic myeloid leukemia (>=65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV (2014) Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause S, Kalmanti L, et al. Journal article, Original article Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV (2014) Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, et al. Journal article